Abstract
INTRODUCTION: The medical chestnut honey is not act only as an antiseptic, it also significantly cleanses and debride the wound in the inflammation phase (saturated sugar solution generates osmotic pressure in the wound, stimulating autolytic debridement; glucose oxidase enzyme help activate protease debridement and promotes antimicrobial and anti-inflammatory activity; kynurenic acid destabilises and inhibits biofilm formation), promotes granulation and stimulates epithelialization (high levels of calcium manganese, zinc, potassium, and proline stimulate granulation and epithelization; high levels of polyphenols and flavonoids have antioxidative activity).

METHODES:
Study 1: To evaluated effects on healing and pain in 19 C2-3 VLUs (venous leg ulcer) treating with medical chestnut honey alginate verssus16 C3 VLUs treating with PHMB foam. In the first week of the study, we proved that alginate dressing with medical chestnut honey cleansed the wound bed faster than polyhexanides, which showed its high efficiency in treating infected venous leg ulcers.

Study 2: We usually use foams to treat wounds once wound bed is clean, that is, for the granulation phase. In our case study, at 7 VLUs, we used medical chestnut honey foam on ulcers whose wound beds were classified as C3 by Falanga´s classification. Within 14 days, the wound beds of all wounds became B3. Medical chestnut honey foams have also been shown to be suitable for debridement and promoting granulation.

Study 3: In case study we treated the patient with VLU on all circumferences of the lower two thirds of the left shin, where wound bed was A2 according to Falanga classification. After 14 days of applied alginate dressing with medical chestnut honey on the half of VLU and hydrofiber dressing with silver to the other half of VLU, the erosions epithelized and healed faster on the side where we used medical chestnut honey.

RESULTS: Medical chestnut honey alginate is an appropriate choice for infected wounds, for fibrin debridement in the inflammatory phase and medical chestnut honey foam accelerates granulation and epithelialization of ulcers.

Abstract
Oily sludge from petrochemical operations imperils Mediterranean coastal ecosystems by discharging hydrocarbons and heavy metals, eroding microbial diversity. At Algeria’s Skikda refinery, a sentinel in arid seaboard zones, this study unveils latent bacterial networks in sludge, highlighting their bioremediation aptitude under Marine and Environmental Bacteriology. Profiling consortia across aging stages (6-, 3-month, fresh) reveals resilient hydrocarbon degraders, informing durable pollution abatement. Samples from Skikda’s treatment  underwent culture-based enumeration via serial dilutions on selective media (nutrient agar, cetrimide for Pseudomonas, Hektoen for Enterobacteriaceae), yielding CFU/g and flagging pathogens (E. coli, streptococci, Clostridium). 16S rRNA metabarcoding of fresh sludge sequenced V3–V4 via Illumina NovaSeq (~100,000 reads/sample); QIIME2, Silva, and UPARSE (97% OTUs) gauged diversity, taxonomy, and phylogenies. Vibrant communities emerged (10⁶–10⁸ CFU/g), led by aerobes/facultative anaerobes: Proteobacteria (45–60%), Firmicutes (20–35%), Bacteroidota (10–15%) proxies for petroleum adaptation. Fresh sludge hosted degraders like Pseudomonas (12%) and Klebsiella (8%), tracking TPH peaks (21,440 mg/kg). Pathogens were sparse (<10³ CFU/g coliforms/streptococci; negligible Clostridium), curbing acute risks but signaling marine bioaccumulation. Aging spurred Firmicutes surges, fostering succession to hardy degraders; Shannon diversity (4.2–5.1) and OTUs (alkane/PAH enzymes) bespoke robustness. Exposing sludge’s bacteriological core, this positions autochthonous microbes as bioaugmentation linchpins for green cleanup. Bridging land-sea pollutant gradients, it catalyzes bacteriological advances, urging microbial synergies to quell coastal hydrocarbon threats and bolster eco-economies in at-risk realms.

Abstract

Introduction: The eustachian valve (EV) is a remnant of the right sinus venosus valve. It remains different in size and shape without much impact on adult life. In 5% to 10% of all endocarditis, are seen in the right side of the heart is involved. Bacteremia, central venous catheter, heart implants, and drug abuse increase the risk of EV vegetation and right heart endocarditis. We are reporting a case of EV endocarditis in patients with Fournier’s gangrene and septic shock. Case presentation: A 45-year-old male patient was admitted into the SICU with Fournier’s gangrene, septic shock, and acute kidney injury. The patient was managed by invasive ventilation, noradrenaline, vasopressin, and renal replacement therapy. He developed Escherichia coli bacteremia and candidemia. We added meropenem and antifungal to the therapy. The transthoracic echocardiography showed EV vegetation and thread-like vegetation in the right coronary sinus, which was confirmed with transesophageal echocardiography. With aggressive therapies, the patient recovered from septic shock, organ dysfunction and was successfully liberated from invasive ventilation. The patient was discharged home on day 27. The antibiotics and antifungal were continued for 6 weeks. Two weeks after discharge, the follow-up echocardiogram was normal, and he was doing well. Discussion: Eustachian valve endocarditis is rare, and should be treated with appropriate, culture- and sensitivity-guided antibiotics and or antifungal therapy for 6 weeks. The reported mortality is up to 17%. The independent risk factors associated with mortality are AKI, the Charlson comorbidity index, congestive heart failure, larger vegetation, and central nervous system involvement. Conclusion: The presence of larger EV, along with E. coli (ESBL) bacteremia and fungemia, increases the risk of right-sided endocarditis, which is rarely reported. An early diagnosis and culture-guided 6-week antimicrobial therapy, will improve the patient’s outcomes.

Abstract
The global rise of antibiotic resistance represents one of the most pressing threats to human and animal health, limiting treatment options and reducing the effectiveness of antimicrobials. Bacteriophages, viruses that specifically infect and destroy bacteria, have re-emerged as highly adaptable antimicrobials, valued for their precision in targeting pathogens, ability to replicate at infection sites, and minimal disruption of beneficial microbiota.

In human medicine, phage therapy is increasingly investigated as a solution for multidrug-resistant infections unresponsive to conventional antibiotics. Clinical and compassionate-use cases report successful outcomes against Pseudomonas aeruginosa, Staphylococcus aureus, and Escherichia coli, including strains resistant to carbapenems and colistin. Promising results have been achieved in chronic wound infections, bacteremia, urinary tract infections, and pulmonary infections in cystic fibrosis patients. Evidence suggests that phages may act not only as a last-resort therapy but also as effective adjuvants to antibiotics, improving bacterial clearance while limiting resistance development.

In veterinary medicine and animal production, phages are applied more selectively as biocontrol tools to limit zoonotic and antimicrobial-resistant bacteria in livestock environments. Their ability to disrupt biofilms on farming and food-processing surfaces underscores their potential in enhancing food safety, although primarily as targeted interventions rather than broad-spectrum solutions.

In addition, phage therapy is gaining recognition in companion animal medicine, where multidrug-resistant infections increasingly challenge veterinary practice. Successful applications in treating skin, wound, and gastrointestinal infections in pets suggest that phages may soon complement or replace antibiotics in small animal care.

Collectively, these developments position bacteriophages as versatile and sustainable tools, supporting a One Health strategy to combat antimicrobial resistance in human, veterinary, and environmental domains.